COPD急性加重早期预警评分比较:DECAF与NEWS评分
该研究在2645例COPD急性加重患者中比较了NEWS、NEWS2、NEWS2All COPD和DECAF评分的预警频率与预后表现。NEWS2All COPD较NEWS2减少12.6%的预警(若豁免不当氧疗评分则减少16.1%),且预后优于NEWS;DECAF的预后表现最优(验证队列AUROC 0.82),但不应替代住院期间重复NEWS2监测。
要点
- NEWS2All COPD可安全减少预警频率,且未增加低风险患者当日死亡。
- DECAF对住院死亡的预后判别优于NEWS和NEWS2,但需外部验证。
- DECAF不能替代住院期间重复NEWS2监测以发现病情恶化。
核心结论
- 与NEWS2相比,NEWS2All COPD可安全降低预警频率。
- DECAF对住院死亡的预后判别优于NEWS和NEWS2,但不能替代住院期间重复NEWS2监测。
研究设计与样本
- 在2645例符合肺功能标准的COPD急性加重患者中,于入院时计算NEWS、NEWS2、NEWS2All COPD和DECAF评分。
- 患者连续就诊于英国六家医院,缺失数据采用多重插补处理。
主要发现
- 与NEWS相比,NEWS2将3.1%的患者重新分类为不需要高级临床医生审阅(评分≥5)。
- NEWS2All COPD减少12.6%的预警,若豁免不当氧疗评分则减少16.1%。
- 被重新分类的患者死亡率低,无患者在被识别为低风险的当天死亡。
- NEWS2All COPD的预后优于NEWS(AUROC 0.72 vs 0.65,p<0.001),与NEWS2相似(AUROC 0.72 vs 0.70,p=0.090)。
- DECAF优于所有评分(验证队列AUROC 0.82),并提供更临床有用的风险分层范围(DECAF=1.2%-25.5%;NEWS2=3.5%-15.4%)。
关键数值与推荐
- NEWS2All COPD较NEWS2减少12.6%的预警(豁免不当氧疗评分时减少16.1%)。
- DECAF验证队列AUROC为0.82;NEWS2All COPD与NEWS2的AUROC分别为0.72和0.70(p=0.090)。
- DECAF风险分层范围为1.2%-25.5%,NEWS2为3.5%-15.4%。
临床怎么用
- COPD急性加重入院时可使用DECAF评分辅助预后判断和临床决策。
- 住院期间应重复监测NEWS2以发现病情恶化,DECAF不能替代动态监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The National Early Warning Score 2 (NEWS2) includes two oxygen saturation scales; the second adjusts target saturations to 88%-92% for those with hypercapnic respiratory failure. Using this second scale in all patients with COPD exacerbation ('NEWS2All COPD') would simplify practice, but the impact on alert frequency and prognostic performance is unknown. Admission NEWS2 score has not been compared with DECAF (dyspnoea, eosinopenia, consolidation, acidaemia, atrial fibrillation) for inpatient mortality prediction. METHODS: NEWS, NEWS2 and NEWS2All COPD and DECAF were calculated at admission in 2645 patients with COPD exacerbation attending consecutively to one of six UK hospitals, all of whom met spirometry criteria for COPD. Alert frequency and appropriateness were assessed for all NEWS iterations. Prognostic performance was compared using the area under the receiver operating characteristic (AUROC) curve. Missing data were imputed using multiple imputation. FINDINGS: Compared with NEWS, NEWS2 reclassified 3.1% patients as not requiring review by a senior clinician (score≥5). NEWS2All COPD reduced alerts by 12.6%, or 16.1% if scoring for injudicious use of oxygen was exempted. Mortality was low in reclassified patients, with no patients dying the same day as being identified as low risk. NEWS2All COPD was a better prognostic score than NEWS (AUROC 0.72 vs 0.65, p<0.001), with similar performance to NEWS2 (AUROC 0.72 vs 0.70, p=0.090). DECAF was superior to all scores (validation cohort AUROC 0.82) and offered a more clinically useful range of risk stratification (DECAF=1.2%-25.5%; NEWS2=3.5%-15.4%). CONCLUSION: NEWS2All COPD safely reduces the alert frequency compared with NEWS2. DECAF offers superior prognostic performance to guide clinical decision-making on admission, but does not replace repeated measures of NEWS2 during hospitalisation to detect the deteriorating patient.
引用
- Echevarria C, Steer J, Bourke SC, et al. Comparison of early warning scores in patients with COPD exacerbation: DECAF and NEWS score. Thorax. 2019. PMID: 31387892. doi:10.1136/thoraxjnl-2019-213470
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。